Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving sorafenib together with bevacizumab works in
treating patients with metastatic colorectal cancer. Sorafenib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Sorafenib and bevacizumab may also stop the growth of tumor cells by
blocking blood flow to the tumor. Giving sorafenib together with bevacizumab may kill more
tumor cells